These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 1929246)

  • 1. Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.
    Markowitz SM; Wells VD; Williams DS; Stuart CG; Coudron PE; Wong ES
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1075-80. PubMed ID: 1929246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.
    Lavoie SR; Wong ES; Coudron PE; Williams DS; Markowitz SM
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1447-51. PubMed ID: 8363374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.
    Arias CA; Singh KV; Panesso D; Murray BE
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2043-7. PubMed ID: 17438057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity.
    Bayer AS; Tu J
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1068-74. PubMed ID: 2118323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
    Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of Enterococcus faecalis to twelve antibiotics, time-kill assays, and high-level aminoglycoside resistance in a university hospital in Argentina.
    Predari SC; Gutiérrez MA; Ribas C; Molinari GS; Santoianni JE
    Rev Argent Microbiol; 1991; 23(2):67-78. PubMed ID: 1815269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility and bactericidal activity studies of four beta-lactamase-producing enterococci.
    Patterson JE; Zervos MJ
    Antimicrob Agents Chemother; 1989 Feb; 33(2):251-3. PubMed ID: 2497706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.
    Hindes RG; Willey SH; Eliopoulos GM; Rice LB; Eliopoulos CT; Murray BE; Moellering RC
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1019-22. PubMed ID: 2506803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci.
    Louie A; Baltch AL; Ritz WJ; Smith RP; Asperilla M
    Chemotherapy; 1993; 39(5):302-9. PubMed ID: 8396526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.
    Ramos MC; Grayson ML; Eliopoulos GM; Bayer AS
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1864-9. PubMed ID: 1329632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
    Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM;
    J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis.
    Rice LB; Eliopoulos GM; Wennersten C; Goldmann D; Jacoby GA; Moellering RC
    Antimicrob Agents Chemother; 1991 Feb; 35(2):272-6. PubMed ID: 1902647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity among high-level aminoglycoside-resistant enterococci.
    Papaparaskevas J; Vatopoulos A; Tassios PT; Avlami A; Legakis NJ; Kalapothaki V
    J Antimicrob Chemother; 2000 Mar; 45(3):277-83. PubMed ID: 10702545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-kill kinetic studies of ampicillin/sulbactam for beta-lactamase-producing enterococci.
    Patterson JE; Farrel P; Zervos MJ
    Diagn Microbiol Infect Dis; 1991; 14(6):495-9. PubMed ID: 1802536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.
    Sahm DF; Koburov GT
    Antimicrob Agents Chemother; 1989 Jan; 33(1):71-7. PubMed ID: 2496659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis.
    Murray BE; Church DA; Wanger A; Zscheck K; Levison ME; Ingerman MJ; Abrutyn E; Mederski-Samoraj B
    Antimicrob Agents Chemother; 1986 Dec; 30(6):861-4. PubMed ID: 3028251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Enterococcus faecalis clinical isolates with 'penicillin-resistant, ampicillin-susceptible' phenotype as reported by Vitek-2 Compact system.
    Tan YE; Ng LS; Tan TY
    Pathology; 2014 Oct; 46(6):544-50. PubMed ID: 25158809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.
    Mobarakai N; Quale JM; Landman D
    Antimicrob Agents Chemother; 1994 Feb; 38(2):385-7. PubMed ID: 8192473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic characterization of a nosocomial outbreak of VanA Enterococcus faecalis.
    Biavasco F; Miele A; Vignaroli C; Manso E; Lupidi R; Varaldo PE
    Microb Drug Resist; 1996; 2(2):231-7. PubMed ID: 9158765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.